This Wall Street Journal story reports on a New England Journal of Medicine-published study of the trial of two potential vaccines against Ebola disease. Overall, it’s a brief but well-constructed article on a much anticipated study of two Ebola candidate vaccines. Independent sourcing helps bolster the piece, and so does the detailed explanation of the current study. Readers are told how these findings fit in with the larger body of work developing a vaccine. That said, we think the story would have been stronger had it been more clear on the industry connections behind the study, and if it had discussed availability of the vaccine–especially if a new outbreak occurs.
Vaccine development for Ebola would be a big step forward in combatting a deadly infection. And it can be tempting for journalists to get caught up in the exciting research developments, but as we’ve discussed, journalists and consumers need to immunize themselves against hype about unproven vaccines. This story takes a balanced approach by pointing out limitations of the current research.
Vaccine pricing is complicated and prices are unknown at this point in development (pre-clinical). The story could have addressed cost as a potential limitation even if price is unknown at this time.
The story is very clear in giving data on the increased antibody levels among study participants getting either of the two vaccines, or the placebo. However, readers of stories about potential vaccines basically want to know if the vaccines will actually prevent the disease, and this trial was only able to show that the vaccines increased a person’s antibody response. The story does, to its credit, include a statement from one expert stating that it isn’t known what level of antibody response is needed to protect against the disease.
The story includes potential harms from the vaccines: “The level of serious adverse events was higher in the placebo group than either vaccine group, and ‘most of the serious adverse events were attributed to malaria.'”
The story appropriately states that this was the “first placebo-controlled study of two vaccines against the Ebola virus.” It is also clear in pointing to the study’s shortcomings, offering several different limitations, such as “Ebola cases in Liberia began to dwindle early in 2015, and the outbreak there was declared over on May 9 of that year. By the time this work was fully under way, it was too late to see if vaccines actually prevented Ebola sickness and death.”
To the reporter’s credit, no disease mongering.
The story included information from an unaffiliated expert, and it alerts readers that pharmaceutical companies developed the two vaccines. That’s good reporting and useful context. However, the story also says that the latest study was conducted by the “U.S. and Liberian governments and elsewhere,” while neglecting to mention that “elsewhere” includes GlaxoSmithKline and Merck (which employs several of the researchers). The story also doesn’t mention that several of the researchers have other economic ties to the companies. This one’s a close call, but there’s not quite enough information to clear our bar.
We’ll give story a not applicable in this category since there currently is no proven successful treatment against Ebola.
The availability of an Ebola vaccine would be reasonable to address. For example, it a new epidemic developed today, would one of these vaccines be used? This is an important clinical point that researchers might have been able to provide information about.
Since hemorrhagic fevers such as Ebola are so deadly, the possibility of new vaccines that might be successful against them is certainly novel enough for a story. In this case, it reports a strong antibody response against the virus suggesting a possible protection against an often-fatal disease. The story does a good job of putting the new studies in context.
This story does not appear to rely on a news release.
Systematic, Criteria-Driven
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like